Rocket


Overview
Financials
News + Filings
Key Docs
Charts
Ownership
Insiders


All
All (ex-4s)
10-K
10-Q
8-K
3,4,5
Proxy
Prospectus
Other
Tags
Inv. presentation
Quarterly results
IGM Biosciences, Inc. (IGMS) Create: Alert

All | News | Filings
Date FiledTypeDescription
10/03/2023 8-K Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements...
Docs: "IGM Biosciences Announces Retirement of Chairman Michael Loberg, Ph.D. from Board of Directors and Appointment of Elizabeth H.Z. Thompson, Ph.D. to Board of Directors"
08/03/2023 8-K Quarterly results
Docs: "IGM Biosciences Announces Second Quarter 2023 Financial Results – Continued progress in clinical development across portfolio – – Public equity offering and concurrent private placement with gross proceeds of $120.0 million – MOUNTAIN VIEW, Calif., August 3, 2023"
05/12/2023 8-K Quarterly results
Docs: "IGM Biosciences Announces First Quarter 2023 Financial Results and Provides Corporate Update – Randomized clinical trial of IGM-8444 plus FOLFIRI and bevacizumab in second line metastatic colorectal cancer underway – – Plans to present additional non-randomized clinical data for 3 mg/kg of IGM-8444 plus FOLFIRI, with and without bevacizumab, in the middle of 2023 – – Plans to begin clinical testing of imvotamab in severe systemic lupus erythematosus and severe rheumatoid arthritis – MOUNTAIN VIEW, Calif., May 12, 2023"
03/21/2023 8-K Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year  Interactive Data
Docs: "AMENDED AND RESTATED BYLAWS OF"
03/10/2023 8-K Regulation FD Disclosure  Interactive Data
01/06/2023 8-K Investor presentation
Docs: "M 2 BINDING SITES 10 BINDING SITES"
11/03/2022 8-K Quarterly results
08/08/2022 8-K Quarterly results
06/24/2022 8-K Quarterly results
06/01/2022 8-K Quarterly results
05/09/2022 8-K Quarterly results
03/30/2022 8-K Entry into a Material Definitive Agreement, Other Events, Financial Statements and Exhibits  Interactive Data
Docs: "Underwriting Agreement, among IGM Biosciences, Inc. and the Representatives",
"Opinion of Wilson Sonsini Goodrich & Rosati",
"IGM Announces Proposed Public Offering",
"IGM Announces Pricing of $200.0 Million Public Offering"
03/29/2022 8-K Entry into a Material Definitive Agreement, Financial Statements and Exhibits  Interactive Data
Docs: "Collaboration and License Agreement by and between IGM Biosciences, Inc. and Genzyme Corporation"
03/29/2022 8-K Quarterly results
Docs: "UNITED STATES SECURITIES AND EXCHANGE COMMISSION",
"IGM Biosciences Announces Fourth Quarter and Full Year 2021 Financial Results and Provides Corporate Update"
01/12/2022 8-K Results of Operations and Financial Condition, Financial Statements and Exhibits  Interactive Data
Docs: "IGM Biosciences, Inc. Financial Information"
11/04/2021 8-K Quarterly results
Docs: "UNITED STATES SECURITIES AND EXCHANGE COMMISSION",
"IGM Biosciences Announces Third Quarter 2021 Financial Results and Provides Corporate Update"
08/09/2021 8-K Quarterly results
Docs: "IGM Biosciences Announces Second Quarter 2021 Financial Results and Provides Corporate Update"
08/04/2021 8-K Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements...
Docs: "FORM 8-K"
07/13/2021 8-K Entry into a Material Definitive Agreement, Financial Statements and Exhibits  Interactive Data
Docs: "First Amendment to Lease between IGM Biosciences, Inc. and Real Property Investments, LLC effective July 1, 2021",
"First Amendment to Lease between IGM Biosciences, Inc. and Real Property Investments, LLC effective July 1, 2021"
05/06/2021 8-K Quarterly results
03/30/2021 8-K Quarterly results
01/28/2021 8-K Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements...
Docs: "for-1"
01/12/2021 8-K Results of Operations and Financial Condition, Financial Statements and Exhibits
Docs: "IGM Biosciences, Inc. Financial Information",
"IGM Biosciences, Inc. Financial Information"
12/09/2020 8-K Entry into a Material Definitive Agreement, Financial Statements and Exhibits
Docs: "UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15 of The Securities Exchange Act of 1934 Date of Report December 8, 2020 IGM Biosciences, Inc. Delaware 001-39045 77-0349194 325 E. Middlefield Road Mountain View, CA 94043 965-7873 Not Applicable Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions : ☐ Written communications pursuant to Rule 425 under the Securities Act ☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act ☐ Pre-commencement communications pursuant to Rule 14d-2 under the Exchange Act ) ☐ Pre-commencement communications pursuant to Rule 13e-4 un...",
"Underwriting Agreement, by and among the Company and the Representatives",
"Form of Pre-Funded Warrant",
"Opinion of Wilson Sonsini Goodrich & Rosati"
12/07/2020 8-K Entry into a Material Definitive Agreement, Other Events, Financial Statements and Exhibits
Docs: "FORM 8-K",
"Form of Registration Rights Agreement, by and between the Registrant and certain securityholders",
"Updated risk factors",
"Corporate presentation"
11/05/2020 8-K Quarterly results
Docs: "UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15 of The Securities Exchange Act of 1934 Date of Report November 5, 2020 IGM Biosciences, Inc. Delaware 001-39045 77-0349194 325 E. Middlefield Road Mountain View, CA 94043 965-7873 Not Applicable Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions : ☐ Written communications pursuant to Rule 425 under the Securities Act ☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act ☐ Pre-commencement communications pursuant to Rule 14d-2 under the Exchange Act ) ☐ Pre-commencement communications pursuant to Rule 13e-4 un...",
"IGM Biosciences Announces Third Quarter 2020 Financial Results and Provides Corporate Update"
08/06/2020 8-K Quarterly results
08/03/2020 8-K Quarterly results
06/12/2020 8-K Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year, Submission of Matters to a Vote of Security Holders...
Docs: "Amended and Restated Bylaws",
"Amended and Restated Bylaws"
05/07/2020 8-K Quarterly results
Docs: "FORM 8-K",
"IGM Biosciences Announces First Quarter 2020 Financial Results and Provides Corporate Update"
03/26/2020 8-K Quarterly results
11/07/2019 8-K Quarterly results
09/20/2019 8-K Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year, Regulation FD Disclosure, Financial Statements and ...
Docs: "Amended and Restated Certificate of Incorporation of the Registrant",
"Amended and Restated Bylaws of the Registrant",
"IGM Biosciences Announces Closing of Initial Public Offering, Including Full Exercise of Underwriters' Option to Purchase Additional Shares"

Rocket Data Systems, Inc. © 2019 | Contact Us | Data Disclaimer | Terms of Use | Privacy